Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,702
  • Shares Outstanding, K 12,527
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,480 K
  • EBIT $ -53 M
  • EBITDA $ -53 M
  • 60-Month Beta 3.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.35

Options Overview Details

View History
  • Implied Volatility 134.64% (-21.17%)
  • Historical Volatility 113.38%
  • IV Percentile 13%
  • IV Rank 20.56%
  • IV High 291.19% on 11/06/25
  • IV Low 94.11% on 07/28/25
  • Expected Move (DTE 4) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 1.99
  • Today's Open Interest 233
  • Open Int (30-Day) 161
  • Expected Range 21.37 to 21.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.42
  • Number of Estimates 2
  • High Estimate -1.06
  • Low Estimate -1.78
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.41 +59.30%
on 11/17/25
23.71 -9.87%
on 12/12/25
+6.91 (+47.79%)
since 11/12/25
3-Month
10.18 +109.93%
on 09/15/25
23.71 -9.87%
on 12/12/25
+10.81 (+102.37%)
since 09/12/25
52-Week
4.90 +336.12%
on 04/23/25
25.97 -17.71%
on 01/03/25
-1.66 (-7.21%)
since 12/12/24

Most Recent Stories

More News
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody...

FBRX : 21.37 (-5.65%)
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata

FBRX : 21.37 (-5.65%)
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming...

FBRX : 21.37 (-5.65%)
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance...

FBRX : 21.37 (-5.65%)
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Additional data continues to support highly differentiated profile for FB102 in celiac disease

FBRX : 21.37 (-5.65%)
Forte Biosciences, Inc. Announces Results and Provides Update

Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata

FBRX : 21.37 (-5.65%)
5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

FBRX : 21.37 (-5.65%)
QSI : 1.2900 (-7.86%)
DUOT : 9.79 (-5.59%)
IBB : 169.42 (-0.51%)
SLXN : 2.81 (-7.57%)
SPY : 681.76 (-1.08%)
XBI : 123.13 (+0.09%)
ZIM : 18.76 (-5.40%)
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild

The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.

FBRX : 21.37 (-5.65%)
VXF : 213.72 (-1.64%)
VTI : 335.99 (-1.14%)
ONEQ : 91.36 (-1.62%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

FBRX : 21.37 (-5.65%)
JAZZ : 167.50 (+1.58%)
MMED.NE : 14.9000 (+9.48%)
ALC : 78.80 (+0.05%)
INCY : 95.41 (-0.72%)
SGEN : 228.74 (-0.07%)
MNMD : 12.55 (-0.32%)
PFE : 25.85 (+0.19%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

FBRX : 21.37 (-5.65%)
MMED.NE : 14.9000 (+9.48%)
INCY : 95.41 (-0.72%)
SGEN : 228.74 (-0.07%)
MNMD : 12.55 (-0.32%)
BMY : 52.41 (+2.36%)

Business Summary

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

See More

Key Turning Points

3rd Resistance Point 25.28
2nd Resistance Point 24.50
1st Resistance Point 22.93
Last Price 21.37
1st Support Level 20.58
2nd Support Level 19.80
3rd Support Level 18.23

See More

52-Week High 25.97
Last Price 21.37
Fibonacci 61.8% 17.92
Fibonacci 50% 15.43
Fibonacci 38.2% 12.95
52-Week Low 4.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar